AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02977078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler casing
Description: Monitors inhaler use
Study NCT02977078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler casing
Description: Monitors inhaler use
Study NCT02977078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Mobile application software linked to inhaler casing
Study NCT04527835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
Description: ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
Study NCT01985022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-ESI
Description: The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
Study NCT01985022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-ESI
Description: The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
Study NCT03315728 — intervention group
Intervention type: OTHER
Intervention: Quality Improvement Strategy
Description: Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
Study NCT01128335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF(1000mg bid) + tacrolimus + standard of care medications
Description: MMF(1000mg bid) + tacrolimus + standard of care medications
Study NCT01128335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (200mg bid) + tacrolimus + standard of care medications
Description: sotrastaurin (200mg bid) + tacrolimus + standard of care medications
Study NCT01128335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Description: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Study NCT01907841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Study NCT01907841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ischemic Preconditioning
Study NCT02405806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low carbohydrate food
Description: low carbohydrate food
Study NCT02405806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard food
Description: standard food
Study NCT01174953 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: finasteride
Description: Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)
Study NCT03371732 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Intervention group
Description: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
Study NCT03371732 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational advises group
Description: Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
Study NCT03165942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcoholic Beverage
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
Study NCT03165942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Alcoholic Beverage
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
Study NCT03165942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Study NCT03165942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Study NCT03160664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100 + Option
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
Study NCT03160664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
Study NCT03160664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study NCT03160664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study NCT03529123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous
Study NCT03529123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous
Study NCT01985022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual-ESI
Description: The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
Study NCT01685073 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MET/CBT
Description: a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
Study NCT03529123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT03529123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT03529123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine (HMR1964)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous
Study NCT03529123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine (HMR1964)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous
Study NCT02496377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous glycine sulfate Tardyferon
Study NCT02496377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Study NCT01685073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT
Description: a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
Study NCT03480438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
Study NCT03979820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Film-coated tablet
Study NCT03979820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT03979820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenelzine sulfate
Description: Film-coated tablet
Study NCT01392573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
Study NCT01392573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
Study NCT02330614 — intervention group
Intervention type: OTHER
Intervention: Bleaching by peroxide carbamide 10%
Description: bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
Study NCT02496377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Study NCT02496377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose Ferinject
Study NCT00493649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
Study NCT00493649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
Study NCT00493649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
Study NCT02861846 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: profile of CSF biomarkers of AD
Description: dosage of biomarker of AD
Study NCT02639286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 304801
Description: 300 mg of ISIS 304801 administered as SC
Study NCT02639286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via SC
Study NCT02312583 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducational online information
Description: Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
Study NCT02312583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iFightDepression online programme
Description: iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression
Study NCT02330614 — intervention group
Intervention type: OTHER
Intervention: Nothing - control group
Description: Only NEO-FFI test , data used as control
Study NCT00806260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
Study NCT03979820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyramine
Description: Capsules
Study NCT00806260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo daily for 4 weeks
Study NCT03486210 — intervention group
Intervention type: BEHAVIORAL
Intervention: Food preference
Description: The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
Study NCT03486210 — intervention group
Intervention type: OTHER
Intervention: Psychological assesment
Description: Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version).
Study NCT02874183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Pharmacist counseling and follow-up phone calls
Study NCT00806260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Study NCT00806260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol placebo
Description: fruit juice
Study NCT02795494 — intervention group
Intervention type: BEHAVIORAL
Intervention: WOMAC questionnaire at baseline
Description: Patient-reported pain, stiffness and physical function outcome score
Study NCT02795494 — intervention group
Intervention type: BEHAVIORAL
Intervention: ASK-P questionnaire at baseline
Description: Patient-reported activity level score
Study NCT02795494 — intervention group
Intervention type: BEHAVIORAL
Intervention: WOMAC questionnaire at 2 weeks
Description: Patient-reported pain, stiffness and physical function outcome score
Study NCT02171689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]- BIBW 2992 MA2
Study NCT00038844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1 H (Alemtuzumab)
Description: Starting Dose of 15 mg by vein daily, 3 days in a row.
Study NCT00038844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 by vein daily, 3 days in a row.
Study NCT00038844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1 gm/m2 by vein daily, 3 days in a row.
Study NCT00038844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
Study NCT03111316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cervidil 10 MG Vaginal Insert
Description: Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Study NCT00126581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00126581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study NCT00126581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00126581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00830570 — intervention group
Intervention type: OTHER
Intervention: CYP 2C9 and VKORC1 Testing for Warfarin
Description: Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
Study NCT03979820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyramine
Description: Capsules
Study NCT03780036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Megaprosthetic Implants the Next Generation (MING)
Description: Use of either porous of porous+hydroxyapathite collars.
Study NCT01445964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol oral administration
Study NCT01445964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol with apple juice 1200 mL
Description: Atenolol oral administration with apple juice 1200 mL
Study NCT01445964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol with apple juice 600 mL
Description: Atenolol oral administration with apple juice 600 mL
Study NCT03979820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tyramine
Description: Capsules
Study NCT04037917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorNeat EverPatch
Description: Covering Ophthalmic Implants
Study NCT02995876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glaze layer
Description: A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
Study NCT03111316 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter
Description: The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
Study NCT02187497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIBR 277
Study NCT02995876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E-max Press layer
Description: A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
Study NCT00546572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
Study NCT00546572 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23vPS
Description: 0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1